Genmab - ADR Stock

$22.60

2.12% yesterday

Nasdaq, Jul 29, 10:00 pm CET

ISIN

US3723032062

Symbol

GMAB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Genmab - ADR Stock price

$22.60

-12.58 35.76% 5Y

Nasdaq, Closing price Tue, Jul 29 2025

-0.49 2.12%

ISIN

US3723032062

Symbol

GMAB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$14.2b

Enterprise Value

$13.8b

Net debt

positive

Cash

$499.3m

Shares outstanding

63.3m

Valuation (TTM | estimate)

P/E

4.0 | 1.4

P/S

11.5 | 25.2

EV/Sales

11.2 | 24.4

EV/FCF

negative

P/B

17.3

Financial Health

Equity Ratio

80.1%

Return on Equity

21.4%

ROCE

42.5%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$1.2b | $564.5m

EBITDA

$397.0m | $1.3b

EBIT

$384.7m | $1.2b

Net Income

$369.9m | $1.0b

Free Cash Flow

$-14.0m

Growth (TTM | estimate)

Revenue

-55.3% | 10.8%

EBITDA

- | 693.0%

EBIT

-56.4% | 626.5%

Net Income

-56.3% | 462.6%

Free Cash Flow

-101.7%

EPS

$5.8

FCF per Share

$-0.2

Short interest

0.6%

Employees

Rev per Employee

$190.0k

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

Genmab - ADR Stock Analysis

Unlock Scores for Free

??

29 Analysts have issued a Genmab - ADR forecast:

21x Buy

72%

7x Hold

24%

More details on Analyst Estimates Including Price Targets

29 Analysts have issued a Genmab - ADR forecast:

Buy

72%

Hold

24%

Sell

Analyst Estimates with Stock Price Targets

Financial data from Genmab - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	1,233 1,233	55% 55% 100%
- Direct Costs	50 50	21% 21% 4%
Gross Profit	1,183 1,183	42% 42% 96%
- Selling and Administrative Expenses	208 208	61% 61% 17%
- Research and Development Expense	561 561	56% 56% 46%
EBITDA	397 397	- 32%
- Depreciation and Amortization	12 12	- 1%
EBIT (Operating Income) EBIT	385 385	56% 56% 31%
Net Profit	370 370	56% 56% 30%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Genmab - ADR Stock News

Neutral

GlobeNewsWire

●

14 days ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025

Company Announcement Net sales of DARZALEX ® in the second quarter of 2025 totaled USD 3,539 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 16, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) prod...

Neutral

GlobeNewsWire

●

29 days ago

Genmab Announces Changes to its Executive Committee

Media Release COPENHAGEN, Denmark; July 1, 2025 Birgitte Stephensen, Executive Vice President and Chief Legal Officer to retire after 23 years with Genmab A/S Greg Mueller joins as new Executive Vice President, General Counsel and Chief Legal Officer, effective July 1 Genmab A/S (Nasdaq: GMAB ) a nnounced today that Birgitte Stephensen, Executive Vice President and Chief Legal Officer, will ret...

Neutral

GlobeNewsWire

●

30 days ago

Completion of Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; June 30, 2025 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2025. On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.

More Genmab - ADR News

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Head office	Denmark
CEO	Jan Winkel
Employees	2,682
Founded	1998
Website	www.genmab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now